Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion type Assertion NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_head.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion description "[The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_provenance.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion evidence source_evidence_literature NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_provenance.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion SIO_000772 15224354 NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_provenance.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion wasDerivedFrom befree-20150227 NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_provenance.
- NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_assertion wasGeneratedBy ECO_0000203 NP323619.RAhaeRxODar0pegi1ZsIy-s6oLsArQc7B_iwmXyTrNAhM130_provenance.